The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer

摘要: Background Evaluation of the prognostic significance a group tumour markers and their ability to predict response chemotherapy may allow better targeting palliative treatment in advanced colorectal cancer. Patients methods Using prospectively acquired database 377 patients (pts) with adenocarcinoma, serum CEA (342 pts), beta HCG (203 AFP (208 CA125 (150 CA-19-9 (76 pts) as well C-erb B-2 (197 pts). Serum were taken prior 5-FU based immunohistochemistry was performed on diagnostic samples Results Tumour poor univariate analysis > or = 5 micrograms/l (p 0.006; median survival (MS 59 weeks vs 38 weeks) 35 U/ml 0.01 MS 51 vs. 30 weeks). elevated at greater than 10 times normal value which correlated prognosis 0.001; 47 weeks), 2) poorly differentiated histology also survival. In multivariate analysis, independent (Hazard Ratio (HR) 1.8; 95% Confidence Internal (CI) 2.8-1.2), 50 (HR 1.6; CI 2.1-1.2), 1.5; 2.3-1.0), CA 125 350 5.0; 9.6-2.6) BHCG 0 IU/l 11.7; 30-4.5). Poor performance status 6.7-5.0) 2.8-1.0) other important factors model. No pretreatment marker chemotherapy. Conclusions This is largest study each disease it clarifies previous conflicting reports. AFP, CA19-9 immunohistochemical stains have no significance. CEA, HCG, cancer do convey an reflect not just burden but aggressive biology.